The Federal Trade Commission announced Friday it has cleared the latest pharmaceutical merger proposal as a string of deals in the industry sweeps across the globe.
Forest Laborites has been cleared to acquire Furiex Pharmaceuticals, a deal made for $1.46 billion, according to reports. Forest first announced in late April that it plans to acquire the company for its gastrointestinal treatment portfolio.
The merger is one of many in the works for the pharmaceutical market, though not all are sure to consummate. Recently, Pfizer failed to acquire AstraZeneca despite several bids that ultimately reached a $119 billion offer. Additionally, Valeant is currently looking to acquire the maker of Botox, Allergan, and has also recently increased its offer.
Full content: Reuters
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Public Interest Groups Push for Rehearing on FCC Net Neutrality Case
Feb 18, 2025 by
CPI
Australian Regulator Backs Virgin Australia-Qatar Airways Alliance
Feb 18, 2025 by
CPI
EU Scales Back AI Regulations to Compete with US in Global Tech Race
Feb 18, 2025 by
CPI
Democratic Lawmakers Raise Concerns Over Musk’s Task Force and Taxpayer Data Security
Feb 18, 2025 by
CPI
UK’s CMA Provisionally Approves Poultry Feed Merger
Feb 18, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – International Criminal Enforcement
Jan 23, 2025 by
CPI
The Antitrust Division’s Recent Work to Combat International Cartels
Jan 23, 2025 by
Emma Burnham & Benjamin Christenson
Information Sharing: The New Frontier of U.S. Antitrust Enforcement
Jan 23, 2025 by
Brian P. Quinn, Casey Kovarik & Michael Tubach
The Key Role of Guidelines on Exchanges of Information Among Competitors and the Divergent Transatlantic Paths
Jan 23, 2025 by
Rosa Abrantes-Metz & Albert Metz
Leniency, Whistleblowers, and Compliance
Jan 23, 2025 by
Richard Powers, Tara O’Malley & Cory Gordon